Skip to main content

Seegene, Shimadzu Ink Molecular Dx Pact

NEW YORK (GenomeWeb News) – Seegene and Shimadzu jointly announced today that they will collaborate on developing molecular diagnostics tests that will run on Shimadzu’s MultiNA high-speed electrophoresis system.
 
Seegene makes the Seeplex family of PCR-based, multi-pathogen tests. The Rockville, Md.-based firm makes screening tests for STDs, respiratory viruses, human papillomavirus, sepsis, and pneumonia, it said.
 
Shimadzu’s MultiNA platform, which is indicated for research use only, uses microchip technology to perform fully automated, high-speed electrophoresis separation, fluorescence detection, and high-sensitivity analysis.
 
Jong-Yoon Chun, founder and CEO of Seegene, said that Shimadzu’s MultiNA platform is “a perfect match for the Seeplex family of multi-pathogen tests.”
 
 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.